NREP
NEW REPRESENTATIVE AT IB RECEIVED
18/12/2025
Voltar para busca
Dado oficial do USPTO
SSHLNP
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
32
Atualização mais recente
03/04/2026
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
13/05/2022
Data de registro
27/08/2024
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/08/2024
Última transação
03/04/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
GB
Examinador
MAJCHER HARTNETT, MEGAN K
Unidade examinadora
N50
Localização atual
FILE REPOSITORY (FRANCONIA)
Titulares e representantes
Titulares
SISAF Ltd
Representantes
Evi T. Christou BANNER & WITCOFF, LTD.
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Nanoparticle substances and nanoparticles for use in industryscience and researchsilicon; silicon for use in industryscience and research; silicon nanoparticle materials for use in industryscience and research; porous silicon nanoparticle materials for use in industryscience and research; lipid nanoparticles for use in industryscience and research; silicon-lipid nanoparticles for use in industryscience and research; silicon-stabilised hybrid lipid nanoparticles for use in industryscience and research; silicon-stabilised lipid nanoparticles for use in industryscience and research; stabilised lipid nanoparticles for use in industryscience and research; chemical materialssilicon for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticals in gene therapy; chemical materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; porous silicon nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-lipid nanoparticle materials for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised hybrid lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; silicon-stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; stabilised lipid nanoparticles for carrying and delivery of chemicalbiochemical and biological substances for use in the manufacture of vaccines; chemical materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising of chemicalbiochemical and biological substances for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acids for use in the manufacture of pharmaceuticalscosmetics and chemicals; chemical materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; porous silicon nanoparticle materials for stabilising of nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-lipid nanoparticle materials for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon-stabilised hybrid lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; silicon- stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals; stabilised lipid nanoparticles for stabilising nucleic acid-lipid complexes for use in the manufacture of pharmaceuticalscosmetics and chemicals
Classe 5
Nanoparticle-based pharmaceutical substances and nanoparticle-based pharmaceutical preparations for medicalveterinary and pharmaceutical purposes namely drug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccinesporous silicon nanoparticle substances and porous silicon nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for medicalveterinary and pharmaceutical purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; nanoparticle substances and nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposes namelydrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and silicon-lipid nanoparticle preparations for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for pharmaceuticalmedical and veterinary diagnosis purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; nanoparticle substances and nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon nanoparticle substances and silicon nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; porous silicon nanoparticle substances and porous silicon nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticle substances and lipid nanoparticle preparations for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles for medicalveterinary and pharmaceutical treatment purposesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; drug delivery agentspharmaceutical nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances ; drug delivery agentspharmaceutical silicon nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentspharmaceutical porous silicon nanoparticle preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentslipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentssilicon-stabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; drug delivery agentsstabilised lipid nanoparticles being pharmaceutical preparations for carrying and delivery of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical silicon nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical porous silicon nanoparticle preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising of chemicalbiochemicalbiological and pharmaceutical substancesdrug delivery agents in the form of compounds that facilitate delivery of a wide range of pharmaceuticals used in the formulation of medicinesvaccinesmedical treatmentsveterinary medicinesveterinary treatmentsveterinary vaccines; pharmaceutical preparations for stabilising nucleic acids; pharmaceutical nanoparticle preparations for stabilising nucleic acids; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acids; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acids; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acids; pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; pharmaceutical porous silicon nanoparticle preparations for stabilising nucleic acid-lipid complexes; lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid- lipid complexes; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; stabilised lipid nanoparticles being pharmaceutical preparations for stabilising nucleic acid-lipid complexes; pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical silicon nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical porous silicon nanoparticle preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and onset of chemicalbiochemicalbiological and pharmaceutical substances; pharmaceutical preparations for controlled release and transfection of nucleic acids; pharmaceutical nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical silicon nanoparticle preparations for controlled release and transfection of nucleic acids; pharmaceutical porous silicon nanoparticle preparations for controlled release and transfection of nucleic acids; lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-lipid nanoparticle materials being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised hybrid lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; silicon-stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids; stabilised lipid nanoparticles being pharmaceutical preparations for controlled release and transfection of nucleic acids
Publicações
Histórico de despachos e eventos da marca no USPTO.
32 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
08/03/2025
FICS
FINAL DISPOSITION NOTICE SENT TO IB
14/02/2025
FIMP
FINAL DISPOSITION PROCESSED
13/02/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
27/11/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/08/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
27/08/2024
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
30/06/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/06/2024
PUBO
PUBLISHED FOR OPPOSITION
11/06/2024
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/06/2024
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
07/06/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/05/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/05/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
11/04/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
11/04/2024
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
11/04/2024
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
27/11/2023
GNFR
FINAL REFUSAL E-MAILED
27/11/2023
CNFR
FINAL REFUSAL WRITTEN
27/11/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
24/10/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
24/10/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
24/10/2023
RFNT
REFUSAL PROCESSED BY IB
17/05/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
26/04/2023
RFRR
REFUSAL PROCESSED BY MPU
26/04/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/03/2023
CNRT
NON-FINAL ACTION WRITTEN
06/03/2023
DOCK
ASSIGNED TO EXAMINER
03/03/2023
MAFR
APPLICATION FILING RECEIPT MAILED
07/01/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
03/01/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/12/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SSHLNP ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.